Implementation of hypoxia measurement into lung cancer therapy

Lung Cancer

Volumn 75, Issue 2, 2012, Pages 146-150

  Meng, Xue ^a   Kong, Feng Ming Spring ^b   Yu, Jinming ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

FAZA; FETNIM; FMISO; Hypoxia; Lung cancer; PET imaging

Indexed keywords

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; HYPOXIA; LUNG CANCER; OXYGEN TISSUE LEVEL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

CELL HYPOXIA; HUMANS; LUNG NEOPLASMS; MISONIDAZOLE; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOSURGERY;

EID: 84855462625     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.09.009     Document Type: Review

References (29)

1. Graves E.E., Maity A., Le Q.T. The tumor microenvironment in non-small cell lung cancer. Semin Radiat Oncol 2010, 20:156-163.
2. Mees G., Dierckx R., Vangestel C., et al. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009, 36:1674-1686.
3. Vikram D.S., Zwerer J.L., Kuppusamy P. Methods for noninvasive imaging of tissue hypoxia. Antioxid Redox Signal 2007, 9:1745-1756.
4. Le Q.T., Chen E., Salim A., et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006, 12:1507-1514.
5. Hung J.J., Yang M.H., Hsu H.S., et al. Prognostic significance of hypoxia-inducible factor-1 α, TWIST 1 and Snail expression in resectable non-small cell lung cancer. Thorax 2009, 12:1082-1089.
6. Llie M., Mazure N.M., Hofman V., et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer 2010, 11:1627-1635.
7. Mack Philip C., Redman Mary W., Chansky Kari, et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy: SWOG study S0003. J Clin Oncol 2008, 26:4771-4776.
8. Koh W.J., Rasey J.S., Evans M.L., et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992, 22:199-212.
9. Rasey J.S., Koh W.J., Evans M.L., et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996, 36:417-428.
10. 18F-FDG PET. J Nucl Med 2006, 47:1921-1926.
11. Yang D.J., Wallace S., Cherif A., et al. Development of F-18-labeled fluoroerythronitromidazole as a PET agent for imaging tumor hypoxia. Radiology 1995, 194:795-800.
12. 18F-FETNIM PET-CT for detection of tumor hypoxia in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi (Chinese) 2010, 6:463-466.
13. 18Ffluoroazomycin arabinoside. J Nucl Med 2005, 46:106-113.
14. Reischl G., Dorow D.S., Cullinane C., et al. Imaging of hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA-first small animal PET results. J Pharm Pharm Sci 2007, 10:203-211.
15. Postema E.J., McEwan A.J., Riauka T.A., et al. Initial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging 2009, 36:1565-1573.
16. Takahashi N., Fujibayashi Y., Yonekura Y., et al. Evaluation of 62Cu-labeled diacetyl-bis(N 4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med 2000, 14:323-328.
17. 18F-FDG in lung cancer. J Nucl Med 2009, 50:1948-1953.
18. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005, 46:253-260.
19. Gagel B., Reinartz P., Demirel C., et al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006, 6:51-57.
20. Koh W.J., Bergman K.S., Rasey J.S., et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995, 33:391-398.
21. 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small cell lung cancer. Clin Lung Cancer 2010, 5:335-340.
22. Dehdashti F., Mintun M.A., Lewis J.S., et al. In vivo assessment of tumor hypoxia in lung cancer with 60CU-ATSM. Eur J Nucl Med Mol Imaging 2003, 30:844-850.
23. Overgaard J., Horsman M.R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996, 6:10-21.
24. Williamson S.K., Crowley J.J., Lara P.N., et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-smallcell lung cancer: Southwest Oncology Group trial S0003. J Clin Oncol 2005, 23:9097-9104.
25. Le Q.T., McCoy J., Williamson S., et al. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clin Cancer Res 2004, 10:5418-5424.
26. Le Q.T., Moon J., Redman M., et al. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol 2009, 27:3014-3019.
27. Baumann P., Nyman J., Lax I., et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 2006, 45:787-795.
28. Koto M., Takai Y., Ogawa Y., et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2007, 85:429-434.
29. Chao K.S., Bosch W.R., Mutic S., et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001, 49:1171-1182.